Antiarrhythmic drug initiation in patients with atrial fibrillation

Progress in Cardiovascular Diseases

Volumn 42, Issue 1, 1999, Pages 75-90

  Pinski, S L ^a   Helguera, M E ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; PROPAFENONE; QUINIDINE; SOTALOL;

BRADYCARDIA; DISEASE PREDISPOSITION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; GENDER; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; OUTPATIENT CARE; PATHOPHYSIOLOGY; PATIENT MONITORING; QT INTERVAL; REVIEW;

EID: 0032870999     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(99)70010-1     Document Type: Article

References (135)

1. PA Wolf JB Mitchell CS Baker Impact of atrial fibrillation on mortality, stroke and hospital costs Arch Intern Med 158 1998 229 234
2. D Bialy MH Lehmann DN Schumacher Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation J Am Coll Cardiol 19 1992 41A (abstr)
3. EB Sgarbossa SL Pinski Pacemaker therapies for atrial fibrillation Prim Cardiol 20 1994 14 20
4. HJ Wellens CP Lau B Luderitz Atrioverter: An implantable device for the treatment of atrial fibrillation Circulation 98 1998 1651 1656
5. M Haissaguerre P Jäis DC Shah Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 339 1998 659 666
6. EL Pritchett Management of atrial fibrillation N Engl J Med 326 1992 1264 1271
7. EN Prystowsky A Katz Atrial fibrillation EJ Topol Textbook of Cardiovascular Medicine 1997 Lippincott-Raven Philadelphia, PA 1661 1693
8. RH Falk Proarrhythmia in patients treated for atrial fibrillation or flutter Ann Intern Med 117 1992 141 150
9. DM Roden RL Woosley RK Primm Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care Am Heart J 111 1986 1088 1093
10. KC Oberg MF O'Toole JL Gallastegui Late proarrhythmia due to quinidine Am J Cardiol 74 1994 192 194
11. WH Maisel KM Kuntz SC Reimold Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital Ann Intern Med 127 1997 281 284
12. AS Jaffe JM Atkins CK Francis Recommended guidelines for in-hospital cardiac monitoring of adults for detection of arrhythmia J Am Coll Cardiol 18 1991 1431 1433
13. EN Prystowsky DW Benson Jr V Fuster Management of patients with atrial fibrillation: A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation 93 1996 1262 1277
14. PJ Podrid Aggravation of arrhythmia: A complication of antiarrhythmic drugs J Cardiovasc Electrophysiol 4 1993 311 319
15. FI Marcus Risks of initiating therapy with sotalol for treatment of atrial fibrillation J Am Coll Cardiol 32 1998 177 180
16. BI Timins JA Gutman JL Haft Disopyramide-induced heart block Chest 79 1981 477 479
17. GR Simons EL Eisenstein LJ Shaw Cost-effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias Am J Cardiol 80 1997 1551 1557
18. PJ Patel YH Zhu CM Lohse The need for hospital monitoring in patients undergoing pharmacological cardioversion for atrial fibrillation Circulation 96 1997 I454 (abstr)
19. PJ Zimetbaum VE Schreckengost DJ Cohen Evaluation of outpatient initiation of antiarrythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation Am J Cardiol 83 1999 450 452
20. ME Helguera SL Pinski P Gupta Is in-hospital initiation of class Ia or Ic antiarrhythmic drugs in patients with atrial fibrillation or atrial flutter justified? Circulation 88 1993 I446 (abstr)
21. ME Helguera S Daunch SL Pinski Predictors of hospital costs in patients undergoing elective in-hospital initiation of antiarrhythmic drug therapy Pacing Clin Electrophysiol 18 1995 828 (abstr)
22. MH Eckman RH Falk SG Pauker Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation Arch Intern Med 158 1998 1669 1677
23. WM Jackman KJ Friday JL Anderson The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis Prog Cardiovasc Dis 31 1988 115 172
24. DM Roden Taking the “idio” out of “idiosyncratic”: Predicting torsades de pointes Pacing Clin Electrophysiol 21 1998 1029 1034
25. DM Roden R Lazzara M Rosen for the SADS Foundation Task Force on LQTS Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions Circulation 94 1996 1996 2012
26. J Wei M Warhen K Murray Absence of HERG and SCN5A mutations in acquired long QT syndrome Circulation 92 1995 I275 (abstr)
27. E Schulze-Bar W Haverkamp M Hordt Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long-QT syndrome Circulation 96 1997 I211 (abstr)
28. C Napolitano SG Priori PJ Schwartz Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes Circulation 96 1997 I211 (abstr)
29. C Donger I Denjoy M Berthet KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome Circulation 96 1997 2778 2781
30. JH Levine J Morganroth AH Kadish Mechanisms and risk factors for proarrhythmia with type IA compared with IC antiarrhythmic drug therapy Circulation 80 1989 1063 1069
31. SH Hohnloser BN Singh Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications J Cardiovasc Electrophysiol 6 1995 920 936
32. RR Makkar BS Fromm RT Steinman Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs JAMA 270 1993 2590 2597
33. MH Lehmann S Hardy D Archibald Sex difference in risk of torsades de pointes with d,l-sotalol Circulation 94 1996 2535 2541
34. MH Lehmann D Frankowvich JJ Baga Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes? Am J Cardiol 79 1997 963 965
35. PM Rautaharju SH Zhou S Wong Sex differences in the evolution of the electrocardiographic QT interval with age Can J Cardiol 8 1992 690 695
36. MH Lehmann DJ MacNeil Sex differences in magnitude of JTc prolongation with d,l-sotalol Circulation 92 1995 I277 (abstr)
37. RE Benton M Sale Y Chen Women have greater QTc prolongation with quinidine than men Circulation 94 1996 I737 (abstr)
38. XK Liu A Katchman MD Dirci Gender difference in the cycle length-dependent QT and potassium currents in rabbits J Pharmacol Exp Ther 285 1998 672 679
39. MD Drici TR Burklow H Vedanandam Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart Circulation 94 1996 1471 1474
40. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction N Engl J Med 321 1989 406 412
41. T Akiyama Y Pawitan H Greenberg Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial Am J Cardiol 68 1991 1551 1555
42. RH Falk Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation Ann Intern Med 111 1989 107 111
43. S Ranger S Nattel Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs Circulation 92 1995 1300 1311
44. JD Minardo JJ Heger WM Miles Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy N Engl J Med 319 1988 257 262
45. WG Stevenson LW Stevenson HR Middlekauff Improving survival for patients with atrial fibrillation and advanced heart failure J Am Coll Cardiol 28 1996 1458 1463
46. JA Reiffel Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter Am Heart J 135 1998 551 556
47. SM Vaziri MG Larson EJ Benjamin Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study Circulation 89 1994 724 730
48. JM Moalic D Charlemagne P Mnsier Cardiac hypertrophy and failureMA disease of adaptation: Modifications in membrane proteins provide a molecular basis for arrhythmogenicity Circulation 87 1993 IV-21 IV26
49. MA Vos SHM de Groot SC Verduyn Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling Circulation 98 1998 1125 1135
50. PG Volders KR Sipido MA Vos Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes Circulation 98 1998 1136 1147
51. JL Bauman RA Bauernfiend JV Hoff Torsade de pointes due to quinidine: Observations in 31 patients Am Heart J 107 1984 425 430
52. GM Vincent KW Timpthy M Leppert The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome N Engl J Med 327 1992 846 852
53. AH Kadish HF Wesiman EP Veltri Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type Ia antiarrhythmic agents Circulation 81 1990 14 19
54. TA Buckingham ZR Bhutto EA Telfer Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs J Cardiovasc Electrophysiol 5 1994 408 411
55. EN Prystowsky Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia Clin Cardiol 17 suppl 2 1994 II-7 II-10
56. SH Hohnloser A van de Loo F Baedeker Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine J Am Coll Cardiol 26 1995 852 858
57. AMJ Choy D Dabar S Dell'Orto Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm Circulation 94 1996 1202 (abstr)
58. P Della Bella C Tondo G Marenzi Polymorphous ventricular tachycardia as undesirable side effect of the association of quinidine treatment with hysteresis ventricular inhibited pacing Eur Heart J 11 1990 1124 1126
59. DS Goldman PA Levine Pacemaker-mediated polymorphic ventricular tachycardia Pacing Clin Electrophysiol 21 1998 1993 1995
60. MK Chung RA Schweikert BL Wilkoff Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk of significant arrhythmia complications J Am Coll Cardiol 32 1998 169 176
61. Y Kimura K Takayangi Y Sakai Torsades de pointes in paced patients with sick sinus syndrome after disopyramide administration Jpn Heart J 35 1994 153 161
62. S Viskin R Fish A Roth Prevention of torsade de pointes in the congenital long QT syndrome: Use of a pause prevention pacing algorithm Heart 79 1998 417 419
63. S Ranger M Talajic R Lemerey Amplification of flecainide-induced ventricular conduction slowing by exercise Circulation 79 1989 1000 1008
64. JK McKibbin WA Pocock JB Barlow Sotalol, hypokalaemia, syncope, and torsade de pointes Br Heart J 51 1984 157 162
65. DM Roden BF Hoffman Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length Circ Res 56 1985 857 867
66. JM Davidenko L Cohen R Goodrow Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium Circulation 79 1989 674 686
67. T Yang DM Roden Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence Circulation 93 1996 407 411
68. AM Choy CC Lang DM Chomsky Normalization of acquired QT prolongation in humans by intravenous potassium Circulation 96 1997 2149 2154
69. JT Hii DG Wyse AM Gillis Propafenone-induced torsade de pointes: Cross-reactivity with quinidine Pacing Clin Electrophysiol 14 1991 1568 1570
70. TA Mattioni TA Zheutlin JJ Sarmiento Amiodarone in patients with previous drug-mediated torsade de pointes: Long-term safety and efficacy Ann Intern Med 111 1989 574 580
71. JT Hii DG Wyse AM Gillis Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone Circulation 86 1992 1376 1382
72. A Kerne D Tzivoni S Gottlieb Atypical ventricular tachycardia (torsades de pointes) induced by amiodarone: Arrhythmia previously induced by quinidine and disopyramide Chest 81 1982 384 386
73. M Clark KJ Friday J Anderson Drug induced torsades de pointes: High concordance rate among type IA antiarrhythmic drugs and amiodarone J Am Coll Cardiol 5 1985 450 (abstr)
74. HR Middlekauff WG Stevenson LA Saxon Amiodarone and torsades de pointes in patients with advanced heart failure Am J Cardiol 76 1995 499 502
75. KA Ellenbogen HF Clemo BS Stambler Efficacy of ibutilide for termination of atrial fibrillation and flutter Am J Cardiol 78 1996 42 45
76. PR Kowey JT VanderLugt JR Luderer Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter Am J Cardiol 78 1996 46 52
77. DJ MacNeil RO Davies D Deitchman Clinical safety profile of sotalol in the treatment of arrhythmias Am J Cardiol 72 1993 44A 50A
78. MJ Chow AA Piergies DJ Bowsher Torsade de pointes induced by N-acetyl procainamide J Am Coll Cardiol 4 1984 621 624
79. D Dancey Z Wulffhart P McEwan Sotalol-induced torsades de pointes in patients with renal failure Can J Cardiol 13 1997 55 58
80. C Funck-Brentano Becquemonst HK Kroemer Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone Clin Pharmacol Ther 55 1994 256 269
81. KA Thompson JJ Murray IA Blair Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes Clin Pharmacol Ther 43 1988 636 642
82. HJ Duff LB Mitchell CF Nath Concentration-response relationships of disopyramide in patients with ventricular tachycardia Clin Pharmacol Ther 45 1989 542 547
83. KR Wyse V Ye TJ Campbell Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity J Cardiovasc Pharmacol 21 1993 316 322
84. PT Pollak AD Sharma SG Carruthers Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations Am J Cardiol 64 1989 1138 1143
85. R Martyn JC Somberg NZ Kerin Proarrhythmia of nonantiarrhythmic drugs Am Heart J 126 1993 201 205
86. H Feroze R Suri D Silverman Torsades de pointes from terfenadine and sotalol given in combination Pacing Clin Electrophysiol 19 1996 1519 1521
87. JC Lin HA Quasny QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine Pharmacotherapy 17 1997 626 630
88. M Ragosta AC Weihl LE Rosenfeld Potentially fatal interaction between erythromycin and disopyramide Am J Med 86 1989 465 466
89. TO Cheng Atrial flutter during quinidine therapy of atrial fibrillation Am Heart J 52 1956 273 289
90. FI Marcus The hazards of using type Ic antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation Am J Cardiol 66 1990 366 367
91. L Bianconi M Mennuni V Lukic Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study J Am Coll Cardiol 28 1996 700 706
92. CJ Murdock AE Kyles JA Yeung-Lai-Wah Atrial flutter in patients treated for atrial fibrillation with propafenone Am J Cardiol 66 1990 755 757
93. HJ Crijns IC van Gelder KI Lie Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment Am J Cardiol 62 1988 1303 1306
94. B Brembilla-Perrot A Terrier de la Chaise L Jacquemin Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics? Arch Mal Coeur Vaiss 90 1997 961 966
95. A Ahsan R Aldridge R Bowes 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide Int J Cardiol 39 1993 88 90
96. MB El-Harari PC Adams Atrial flutter with 1:1 atrioventricular conduction caused by propafenone Pacing Clin Electrophysiol 21 1998 1999 2001
97. P Denes A Gabster SK Huang Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy Am J Cardiol 48 1981 9 15
98. AK Bhandari JL Anderson EM Gilber the Flecainide Supraventricular Tachycardia Study Group Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring study Am Heart J 124 1992 381 386
99. RF Gilmour Jr ML Riccio EH Locati Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation J Am Coll Cardiol 30 1997 209 217
100. EH Locati P Maisonblanche P Dejode Spontaneous sequences of onset of torsade de pointes in patients with prolonged repolarization: Quantitative analysis of Holter recordings J Am Coll Cardiol 25 1995 1564 1575
101. HL Kennedy Ambulatory (Holter) electrocardiographic technology Cardiol Clin 10 1992 341 359
102. F Roche JM Gaspoz V Pichot Accuracy of an automatic and patient-triggered long-term solid memory ambulatory cardiac event recorder Am J Cardiol 80 1997 1095 1098
103. A Murray NB McLaughlin JP Bourke Errors in manual measurement of QT intervals Br Heart J 71 1994 386 390
104. A Roth Y Bloch Y Villa The CB-12L: A new device for transtelephonic transmission of a 12-lead electrocardiogram Pacing Clin Electrophysiol 20 1997 2243 2247
105. DM Roden Role of the electrocardiogram in determining electrophysiologic end points of drug therapy Am J Cardiol 62 1988 34H 38H
106. JL Willems EO Robles de Medina R Bernard Criteria for intraventricular conduction disturbances and pre-excitation J Am Coll Cardiol 5 1985 1261 1275
107. J Morganroth LN Horowitz Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram Am J Cardiol 53 1984 89B 94B
108. R Padrini D Piovan M Busa Pharmacodynamic variability of flecainide assessed by QRS changes Clin Pharmacol Ther 53 1993 59 64
109. MS Stanton Class I antiarrhythmic drugs: Quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, phenytoin, moricizine, flecainide, propafenone ed 2 DP Zipes J Jalife Cardiac Electrophysiology: From Cell to Bedside 1995 Saunders Philadelphia, PA 1296 1316
110. RL Woosley M Sale QT interval: A measure of drug action Am J Cardiol 72 1993 36 43
111. DM Roden Current status of class III antiarrhythmic drug therapy Am J Cardiol 72 1993 44 49
112. JL Willems P Arnaud JH van Bemmel Assessment of the performance of electrocardiographic computer programs with the use of a reference data base Circulation 71 1985 523 534
113. J Morganroth Relations of QTc prolongation on the electrocardiogram to torsade de pointes: Definitions and mechanisms Am J Cardiol 72 1993 10 13
114. DM Roden A practical approach to torsades de pointes Clin Cardiol 20 1997 285 290
115. G Malfatto G Beria S Sala Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome J Am Coll Cardiol 23 1994 296 301
116. SG Priori DW Mortara C Napolitano Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome Circulation 96 1997 3006 3012
117. CM Blatt S Lampert TB Graboys Is exercise testing safe in patients treated with flecainide for atrial arrhythmia? Am Heart J 126 1993 268 269
118. JA Wang CP Lau YT Tai Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease Clin Cardiol 18 1995 140 144
119. JA Reiffel J Correia Structural heart disease: Its importance in association with antiarrhythmic drug therapy Clin Cardiol 17 suppl 2 1994 II3 II6
120. AL Waldo EN Prystowsky Drug treatment of atrial fibrillation in the managed care era Am J Cardiol 81 1998 23C 29C
121. KJ Hellestrand AW Nathan RS Bexton Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds Am J Cardiol 53 1984 30B 38B
122. S Juul-Möller N Edvardsson N Rehnqvist-Ahlberg Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation Circulation 82 1990 1932 1939
123. RG Tieleman IC Van Gelder HJ Crijns Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 31 1998 167 173
124. Amiodarone Trials Meta-Analysis Investigators Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials Lancet 350 1997 1417 1424
125. SL Winters RG Sachs JH Curwin Nonsustained polymorphic ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy: Management with intravenous magnesium sulfate Chest 111 1997 1454 1457
126. A Natale G Tomassoni S Beheiry Safety of outpatient initiation of amiodarone treatment in patients with atrial fibrillation: Prospective analysis Circulation 98 1998 I18
127. MS Weinfeld WG Drazner WG Stevenson Early efficacy and complications of initiating amiodarone for atrial fibrillation in advanced heart failure J Am Coll Cardiol 31 suppl A 1998 33A abstr
128. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators Atrial fibrillation follow-up investigation of rhythm managementMThe AFFIRM study design Am J Cardiol 79 1997 1198 1202
129. MC Wijffels CJ Kirchhof R Dorland Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
130. A Auricchio H Klein CJ Geller Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation Am J Cardiol 81 1998 1253 1256
131. AL Waldo AJ Camm H deRuyter The effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction Lancet 348 1996 7 12
132. R Karam S Marcello RR Brooks Azimilide dihydrochloride, a novel antiarrhythmic agent Am J Cardiol 81 1998 40D 46D
133. DR Van Wagoner AL Pond PM McCarthy Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation Circ Res 80 1997 772 781
134. L Yue J Feng R Gaspo Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation Circ Res 81 1997 512 525
135. MR Franz PL Karasik C Li Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter J Am Coll Cardiol 30 1997 1785 1792